Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer

TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI and RYOICHI IMAMURA
Anticancer Research June 2025, 45 (6) 2563-2573; DOI: https://doi.org/10.21873/anticanres.17628
TOMOHIRO MATSUO
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tomo1228{at}nagasaki-u.ac.jp
YASUYOSHI MIYATA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNKI HARADA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ITSUHO ITOH
2Department of Urology, Sasebo City General Medical Center, Sasebo, Nagasaki, Japan;
3Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUYOSHI MATSUDA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIHIRO ASAI
4Department of Urology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUBASA KONDO
5Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKI KURATA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
6Department of Urology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUZUNA SAKAI
7Department of Urology, Japan Community Health Care Organization, Isahaya General Hospital, Nagasaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDENORI ITOH
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENSUKE MITSUNARI
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOICHI IMAMURA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 45 (6)
Anticancer Research
Vol. 45, Issue 6
June 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI, RYOICHI IMAMURA
Anticancer Research Jun 2025, 45 (6) 2563-2573; DOI: 10.21873/anticanres.17628

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI, RYOICHI IMAMURA
Anticancer Research Jun 2025, 45 (6) 2563-2573; DOI: 10.21873/anticanres.17628
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab
  • Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
  • Google Scholar

More in this TOC Section

  • Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab
  • Delayed Initiation of Postoperative S-1 Adjuvant Chemotherapy Worsens Prognosis After Gastric Cancer Recurrence
  • Clinical Outcomes of the Optimized Weekly 8-Gy Palliative Radiotherapy Regimen
Show more Clinical Studies

Keywords

  • pembrolizumab
  • third-line treatment
  • urothelial cancer
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire